Literature DB >> 20461887

Heat-labile enterotoxins as adjuvants or anti-inflammatory agents.

Shuang Liang1, George Hajishengallis.   

Abstract

Escherichia coli and Vibrio cholerae produce structurally related AB5-type heat-labile enterotoxins, which are classified into two major types. The Type I subfamily includes cholera toxin and E. coli LT-I, whereas the Type II subfamily comprises LT-IIa and LT-IIb. In addition to their roles in microbial pathogenesis, the enterotoxins are widely and intensively studied for their exceptionally strong adjuvant and immunomodulatory activities, which are not necessarily dependent upon their abilities to elevate intracellular cAMP levels. Despite general structural similarities, these molecules, in intact or derivative form, display notable differences in their interactions with gangliosides or Toll-like receptors. This divergence results in differential immune response outcomes, the underlying mechanisms of which remain largely uncharacterized. Whereas the study of these molecules has been pivotal in understanding basic mechanisms of immune regulation, a formidable challenge is to dissociate toxicity from useful properties that can be exploited in vaccine development or for the treatment of autoimmune inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20461887      PMCID: PMC2819675          DOI: 10.3109/08820130903563998

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  77 in total

Review 1.  Toll-like receptors: critical proteins linking innate and acquired immunity.

Authors:  S Akira; K Takeda; T Kaisho
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

2.  A mutant cholera toxin B subunit that binds GM1- ganglioside but lacks immunomodulatory or toxic activity.

Authors:  A T Aman; S Fraser; E A Merritt; C Rodigherio; M Kenny; M Ahn; W G Hol; N A Williams; W I Lencer; T R Hirst
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

3.  alpha4 integrins and L-selectin differently orchestrate T-cell activity during diabetes prevention following oral administration of CTB-insulin.

Authors:  Caroline Aspord; Cecil Czerkinsky; Annie Durand; Anne Stefanutti; Charles Thivolet
Journal:  J Autoimmun       Date:  2002-12       Impact factor: 7.094

Review 4.  Lipid rafts and signal transduction.

Authors:  K Simons; D Toomre
Journal:  Nat Rev Mol Cell Biol       Date:  2000-10       Impact factor: 94.444

5.  Nasal administration of cholera toxin (CT) suppresses clinical signs of experimental autoimmune encephalomyelitis (EAE).

Authors:  M Yura; I Takahashi; S Terawaki; T Hiroi; M N Kweon; Y Yuki; H Kiyono
Journal:  Vaccine       Date:  2001-10-12       Impact factor: 3.641

6.  The IL-10-producing competence of Th2 cells generated in vitro is IL-4 dependent.

Authors:  Itzhak Mendel; Ethan M Shevach
Journal:  Eur J Immunol       Date:  2002-11       Impact factor: 5.532

7.  cAMP-induced Interleukin-10 promoter activation depends on CCAAT/enhancer-binding protein expression and monocytic differentiation.

Authors:  Susanne Brenner; Susanna Prösch; Katja Schenke-Layland; Ulrike Riese; Ulrike Gausmann; Cornelia Platzer
Journal:  J Biol Chem       Date:  2002-12-18       Impact factor: 5.157

Review 8.  Interleukin-12 and the regulation of innate resistance and adaptive immunity.

Authors:  Giorgio Trinchieri
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

9.  Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation.

Authors:  Martha Triantafilou; Kensuke Miyake; Douglas T Golenbock; Kathy Triantafilou
Journal:  J Cell Sci       Date:  2002-06-15       Impact factor: 5.285

10.  Escherichia coli heat-labile enterotoxin B subunit prevents autoimmune arthritis through induction of regulatory CD4+ T cells.

Authors:  Jeffrey A Luross; Tricia Heaton; Timothy R Hirst; Michael J Day; Neil A Williams
Journal:  Arthritis Rheum       Date:  2002-06
View more
  24 in total

Review 1.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

2.  Recognition of the microbiota by Nod2 contributes to the oral adjuvant activity of cholera toxin through the induction of interleukin-1β.

Authors:  Donghyun Kim; Yu-Mi Kim; Wan-Uk Kim; Jong-Hwan Park; Gabriel Núñez; Sang-Uk Seo
Journal:  Immunology       Date:  2019-09-02       Impact factor: 7.397

3.  Nanoemulsion nasal adjuvant W₈₀5EC induces dendritic cell engulfment of antigen-primed epithelial cells.

Authors:  Andrzej Myc; Jolanta F Kukowska-Latallo; Douglas M Smith; Crystal Passmore; Tiffany Pham; Pamela Wong; Anna U Bielinska; James R Baker
Journal:  Vaccine       Date:  2012-12-25       Impact factor: 3.641

4.  Patching it together: epicutaneous vaccination with heat-labile Escherichia coli toxin against birch pollen allergy.

Authors:  S S Killingbeck; M Q Ge; A Haczku
Journal:  Allergy       Date:  2017-01       Impact factor: 13.146

Review 5.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 6.  Type II heat-labile enterotoxins: structure, function, and immunomodulatory properties.

Authors:  George Hajishengallis; Terry D Connell
Journal:  Vet Immunol Immunopathol       Date:  2012-09-26       Impact factor: 2.046

7.  LT-IIc, a new member of the type II heat-labile enterotoxin family, exhibits potent immunomodulatory properties that are different from those induced by LT-IIa or LT-IIb.

Authors:  Hesham F Nawar; Christopher J Greene; Chang Hoon Lee; Lorrie M Mandell; George Hajishengallis; Terry D Connell
Journal:  Vaccine       Date:  2010-11-21       Impact factor: 3.641

8.  Distinctive immunomodulatory and inflammatory properties of the Escherichia coli type II heat-labile enterotoxin LT-IIa and its B pentamer following intradermal administration.

Authors:  Camila Mathias-Santos; Juliana F Rodrigues; Maria Elisabete Sbrogio-Almeida; Terry D Connell; Luís C S Ferreira
Journal:  Clin Vaccine Immunol       Date:  2011-06-15

9.  Characterization of antigen-presenting cells induced by intragastric immunization with recombinant chimeric immunogens constructed from Streptococcus mutans AgI/II and type I or type II heat-labile enterotoxins.

Authors:  W Zhao; Z Zhao; M W Russell
Journal:  Mol Oral Microbiol       Date:  2011-03-31       Impact factor: 3.563

10.  Use of inactivated Escherichia coli enterotoxins to enhance respiratory mucosal adjuvanticity during vaccination in swine.

Authors:  Roger W Barrette; Steven M Szczepanek; Debra Rood; Sreerupa Challa; Naomi Avery; Michael Vajdy; Ed Kramer; Luis Rodriguez; Lawrence K Silbart
Journal:  Clin Vaccine Immunol       Date:  2011-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.